Episode 57: The KOMET-007 Trial
Unable to add items
Sorry, we're unable to add the item because your cart is already full.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Failed to remove from Wish List.
Please try again later
Adding to library failed
Please try again
Unable to follow podcast
Unable to unfollow podcast
-
Narrated by:
-
By:
Summary
Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.
A must listen - please share subscribe, and join the conversation.
adbl_web_anon_alc_button_suppression_t1
No reviews yet